BERKELEY, CA (UroToday.com) - Luteinizing hormone-releasing hormone analogues are a cornerstone in the management of many clinical situations in prostate cancer patients.
The multiplicity of drugs make it difficult to decide which is the best drug to prescribe to each patient. Whether or not the different luteinizing hormone-releasing hormone analogues belong to the same drug class is only merely supposed. This study adds a systematic review of the literature in order to determine whether or not the luteinizing hormone-releasing hormone analogues available for prescription belong to the same drug class (same family, similar chemical structure, mechanism of action, and efficacy). The current evidence available is not enough to support a presumed drug class effect of the various analogues in the treatment of prostate carcinoma....View or save the Mini Review as a .pdf file
Santiago Vilar González* and Xavier Maldonado Pijuan†
*Radiation Oncology Department, Instituto Medicina Oncológica y Molecular de Asturias, Oviedo, †Radiation Oncology Department, Hospital General Vall d’Hebrón, Barcelona, Spain
More BJUI Mini Reviews and Archives
